Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced, under the terms of the agreement, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day volume weighted average price and a 51% premium to the cl

Proposed Merger Represents a Compelling 59% Premium to the 90-Day VWAP Prior to Announcement STAAR's Business Risks and Challenges are Increasing and Competition is Intensifying China Net Sales, which Represent Approximately Half of STAAR's Consolidated Net Sales, Have Declined Since 2023, and Procedure Volumes Remain Weak Broadwood Partners' Claims Against the Merger are Flawed and Misleading and Reflect a Misunderstanding of STAAR's Standalone Challenges, Value, and Potential Buyer Interest in STAAR STAAR's Stock Traded at $18.49 per Share Prior to Announcement – If the Merger is not Approved, STAAR Expects its Valuation Would Face Considerable Downward Pressure, Especially in Lig

Outlines Its Belief that the Proposed Transaction Is the Product of Bad Timing, a Flawed Process, and Significant Conflicts of Interest Broadwood Believes the Transaction Delivers Less Value than Alternatives, Including a Properly Run Strategic Alternatives Process or Improved Execution as a Standalone Business Sends Letter to STAAR Stockholders Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood"), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) today announced that it has filed a definitive proxy statement and GREEN proxy card with the U.S. Securities and Exchange Commission (the "SEC

Reinforces STAAR Board's Determination that Alcon Merger Maximizes Stockholder Value and is Best Path Forward for STAAR Stockholders STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the 45-day "window shop" period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE:ALC). The "window shop" period expired at 11:59 p.m., Eastern Time, on September 19, 2025, and no competing acquisition proposal was received despite Broadwood Partners' active exploration of alternative buyers over the past 45 days. "The expi

Issues Open Letter to Shareholders Outlining Its Belief that the Proposed Merger Materially Undervalues STAAR Contends that STAAR's Board Failed In Its Responsibilities by Not Running a Thorough Process and Relying on Undue Skepticism about the Company's Prospects Shareholders Deserve Fair Value for the Company Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR") (NASDAQ:STAA), today announced its opposition to the Company's proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025. Yunqi Capital released the following open lette

Provides Greater Value than STAAR Could Achieve on a Standalone Basis in the Foreseeable Future and is the Best Path Forward for STAAR Stockholders Files Definitive Proxy Materials and Mails Letter to STAAR Stockholders Encourages Stockholders to Vote "FOR" the Value Maximizing Alcon Merger Today STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with the Company's pending merger with Alcon (SIX/NYSE:ALC). STAAR will hold a Special Meeting of Stockholders

UNITY VCS provides statistically significant set-up and tear-down efficiencies compared to CONSTELLATION Vision System or CENTURION Vision System1,2 Statistically significant reductions in total energy delivered into the eye were observed with UNITY VCS compared to CENTURION Vision System with ACTIVE SENTRY during cataract surgery2 Turnover time savings with UNITY VCS allow for more efficient use of the operating room for both cataract and vitreoretinal surgeries1,2 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, announced results from time and motion studies demonstrating superior efficiency* with UNITY® Vitreoretinal Cataract Syst

Cutting-edge technologies UNITY VCS, Clareon Vivity, Voyager DSLT, now commercially available in Europe, to be featured at Alcon booth and throughout conference activities New data on Vivity IOLs underpin positive outcomes, patient satisfaction after cataract surgery in patients with special considerations1-3 Reduced breakthrough pain medication use and less patient discomfort demonstrated in a study performing cataract surgery at more physiologic IOP with CENTURION with Active Sentry4,5 Wavelight plus head-to-head data demonstrate outstanding refractive outcomes6,7 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, will present com

Alcon (SIX/NYSE:ALC) CEO David Endicott will present at the 2025 Baird Global Healthcare Conference on Tuesday, September 9, 2025, at 9:05 a.m. ET. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than

Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

Analyst downgraded Alcon from Overweight to Neutral

Deutsche Bank downgraded Alcon from Buy to Hold

BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously

Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $110.00 from $107.00 previously

BofA Securities upgraded Alcon from Neutral to Buy

Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $106.00 from $108.00 previously

Redburn Atlantic upgraded Alcon from Neutral to Buy

Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $108.00 from $103.00 previously

Needham reiterated coverage of Alcon with a rating of Buy

Redburn Atlantic upgraded Alcon from Sell to Neutral

6-K - ALCON INC (0001167379) (Filer)

DEFM14A - ALCON INC (0001167379) (Filer)

6-K - ALCON INC (0001167379) (Filer)

6-K - ALCON INC (0001167379) (Filer)

SD - ALCON INC (0001167379) (Filer)

6-K - ALCON INC (0001167379) (Filer)

6-K - ALCON INC (0001167379) (Filer)

20-F - ALCON INC (0001167379) (Filer)

6-K - ALCON INC (0001167379) (Filer)

6-K - ALCON INC (0001167379) (Filer)

Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f

Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years of experience in the f

Leverages Alcon's global scale with Aurion's cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion's lead asset received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration (FDA) Positions Alcon at the leading edge of biopharma applications in ophthalmology with the potential to advance the first-ever corneal cell therapy candidate Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye d

Full-year 2024 sales of $9.8 billion, up 5%, or up 6% constant currency1 (cc) Full-year 2024 diluted EPS of $2.05, up 5% on a reported basis, or up 11% cc; core diluted EPS2 of $3.05 up 11% on a reported basis, or up 16% cc Generated record $2.1 billion of cash from operations in full-year 2024; record free cash flow3 of $1.6 billion, up 120% Announced share repurchase authorization to offset dilution from associate equity incentive plans Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5

Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarte

Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as

First-quarter 2024 sales of $2.4 billion, up 5%, or 7% constant currency1 (cc) First-quarter 2024 diluted EPS of $0.50, up 43%, or 62% cc; core diluted EPS2 of $0.78 up 11%, or 21% cc First-quarter 2024 cash from operations of $341 million; free cash flow3 of $229 million, up $248 million year-over year Dividend of CHF 0.24 per share approved by shareholders at the Annual General Meeting on May 8, 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2024. For the first quarter of 2024, sales were $2.4 billion, an increase of 5% on a reported basis and 7% on a consta

SC 13G - ALCON INC (0001167379) (Subject)

SC 13G/A - ALCON INC (0001167379) (Subject)

SC 13G/A - ALCON INC (0001167379) (Subject)

SC 13G/A - ALCON INC (0001167379) (Subject)

SC 13G/A - ALCON INC (0001167379) (Subject)